Brainstorm Cell Therapeutics (NASDAQ: BCLI) reported Q3 EPS of ($1.80), $1.76 worse than the analyst estimate of ($0.04).

For earnings history and earnings-related data on Brainstorm Cell Therapeutics (BCLI) click here.